26 August 2020 – MPA Webinar Series

Event #1 – Wed 26th August from 7pm to 830pm Topics: Dermatology and Melanoma Surgery Please register via the Eventbrite link: https://www.eventbrite.com.au/e/dermatology-and-melanoma-surgery-a-discussion-with-our-specialists-registration-116189932215?aff=ebdssbeac >> DOWNLOAD PDF for full details

Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website http://australasianmelanoma.org/

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Cancer in the News

Feature Articles

World Melanoma Month 2021 – SBS News

On Saturday MPA launched a major public awareness campaign to highlight World Melanoma Month.

READ MORE >

Posted in Melanoma News, Patients, Latest News

Relatlimab-nivolumab combination extends PFS in metastatic melanoma

A trial designed to evaluate the addition of relatlimab to nivolumab for untreated metastatic or unresectable melanoma met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

READ MORE >

Posted in Melanoma News, Health Professionals, Clinical Trials

Combination Treatment Improves Relapse-Free Survival Time

Patients with stage III melanoma receiving a combination treatment of dabrafenib (Tafinlar) and trametinib (Mekinist) achieved longer restricted mean survival times (RMST) compared to placebo, according to recent study results.1

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest

Relatlimab/Nivolumab Improves PFS in Previously Untreated Metastatic or Unresectable Melanoma

The fixed-dose combination of relatlimab plus nivolumab (Opdivo) was found to improve progression-free survival (PFS) over nivolumab alone in patients with previously untreated metastatic or unresectable melanoma, meeting the primary end point of the phase 2/3 RELATIVITY-047 (CA224-047; NCT03470922) trial.1

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest